{"id":"https://openalex.org/W4361815427","doi":"https://doi.org/10.1158/1078-0432.22480008","title":"Supplementary Tables 1-5 from Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study","display_name":"Supplementary Tables 1-5 from Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study","publication_year":2023,"publication_date":"2023-03-31","ids":{"openalex":"https://openalex.org/W4361815427","doi":"https://doi.org/10.1158/1078-0432.22480008"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.22480008","doi":"https://doi.org/10.1158/1078-0432.22480008","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.22480008","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Tables_1-5_from_Efficacy_and_Safety_of_Duvelisib_Following_Disease_Progression_on_Ofatumumab_in_Patients_with_Relapsed_Refractory_CLL_or_SLL_in_the_DUO_Crossover_Extension_Study/22480008/1/files/39931521.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"supplementary-materials","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Tables_1-5_from_Efficacy_and_Safety_of_Duvelisib_Following_Disease_Progression_on_Ofatumumab_in_Patients_with_Relapsed_Refractory_CLL_or_SLL_in_the_DUO_Crossover_Extension_Study/22480008/1/files/39931521.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5063755644","display_name":"Matthew Steven Davids","orcid":"https://orcid.org/0000-0003-4529-2003","observed_orcids":["https://orcid.org/0000-0003-4529-2003"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Matthew S. Davids","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002467749","display_name":"Bryone Jean Kuss","orcid":"https://orcid.org/0000-0002-5811-1331","observed_orcids":["https://orcid.org/0000-0002-5811-1331"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Bryone J. Kuss","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047631289","display_name":"Peter Hillmen","orcid":"https://orcid.org/0000-0001-5617-4403","observed_orcids":["https://orcid.org/0000-0001-5617-4403"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Peter Hillmen","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-5617-4403","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039819830","display_name":"Marco Montillo","orcid":"https://orcid.org/0000-0003-0010-032X","observed_orcids":["https://orcid.org/0000-0003-0010-032X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Marco Montillo","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056554686","display_name":"Carol Moreno","orcid":"https://orcid.org/0000-0003-3275-0271","observed_orcids":["https://orcid.org/0000-0003-3275-0271"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Carol Moreno","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044422916","display_name":"James H. Essell","orcid":"https://orcid.org/0000-0002-9173-0310","observed_orcids":["https://orcid.org/0000-0002-9173-0310"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"James Essell","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010100538","display_name":"Nicole Lamanna","orcid":"https://orcid.org/0000-0003-3331-9491","observed_orcids":["https://orcid.org/0000-0003-3331-9491"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Nicole Lamanna","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Zsolt Nagy","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Zsolt Nagy","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034517642","display_name":"Constantine Si Lun Tam","orcid":"https://orcid.org/0000-0002-9759-5017","observed_orcids":["https://orcid.org/0000-0002-9759-5017"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Constantine S. Tam","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019866348","display_name":"Stephan Stilgenbauer","orcid":"https://orcid.org/0000-0002-6830-9296","observed_orcids":["https://orcid.org/0000-0002-6830-9296"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Stephan Stilgenbauer","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087770514","display_name":"Paolo Ghia","orcid":"https://orcid.org/0000-0003-3750-7342","observed_orcids":["https://orcid.org/0000-0003-3750-7342"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Paolo Ghia","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-3750-7342","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014405902","display_name":"Julio Delgado","orcid":"https://orcid.org/0000-0002-5157-4376","observed_orcids":["https://orcid.org/0000-0002-5157-4376"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Julio Delgado","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006302059","display_name":"Stephanie Lustgarten","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Stephanie Lustgarten","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074838425","display_name":"David T. Weaver","orcid":"https://orcid.org/0000-0001-8398-3919","observed_orcids":["https://orcid.org/0000-0001-8398-3919"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"David T. Weaver","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065694446","display_name":"Hagop Youssoufian","orcid":"https://orcid.org/0009-0003-1673-8384","observed_orcids":["https://orcid.org/0009-0003-1673-8384"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hagop Youssoufian","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5113865605","display_name":"Ulrich Jaeger","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ulrich J\u00e4ger","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10950","display_name":"Acute Lymphoblastic Leukemia research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/duvelisib","display_name":"duvelisib","score":0.9990000128746033},{"id":"https://openalex.org/keywords/ofatumumab","display_name":"ofatumumab","score":1.0},{"id":"https://openalex.org/keywords/relapsed-refractory-cll","display_name":"relapsed/refractory CLL","score":0.9010000228881836},{"id":"https://openalex.org/keywords/small-lymphocytic-lymphoma","display_name":"small lymphocytic lymphoma","score":0.8899999856948853},{"id":"https://openalex.org/keywords/bruton-tyrosine-kinase-inhibitors","display_name":"BTK inhibitors","score":0.5849999785423279},{"id":"https://openalex.org/keywords/treatment-emergent-adverse-events","display_name":"treatment-emergent adverse events","score":0.753000020980835},{"id":"https://openalex.org/keywords/serious-adverse-events","display_name":"serious adverse events","score":0.6510000228881836},{"id":"https://openalex.org/keywords/best-overall-response","display_name":"best overall response","score":0.7680000066757202},{"id":"https://openalex.org/keywords/duration-of-response","display_name":"duration of response","score":0.7979999780654907},{"id":"https://openalex.org/keywords/patient-disposition","display_name":"patient disposition","score":0.8569999933242798}],"concepts":[{"id":"https://openalex.org/C2778714382","wikidata":"https://www.wikidata.org/wiki/Q410656","display_name":"Ofatumumab","level":4,"score":0.6623395085334778},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6410309076309204},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.5271524786949158},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.4832516312599182},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.44473034143447876},{"id":"https://openalex.org/C45235069","wikidata":"https://www.wikidata.org/wiki/Q278425","display_name":"Table (database)","level":2,"score":0.4131772220134735},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4094977378845215},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0927375853061676},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.08703294396400452},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.07296651601791382},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.0},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0},{"id":"https://openalex.org/C124101348","wikidata":"https://www.wikidata.org/wiki/Q172491","display_name":"Data mining","level":1,"score":0.0},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0}],"mesh":[],"locations_count":3,"locations":[{"id":"doi:10.1158/1078-0432.22480008","doi":"https://doi.org/10.1158/1078-0432.22480008","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.22480008","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Tables_1-5_from_Efficacy_and_Safety_of_Duvelisib_Following_Disease_Progression_on_Ofatumumab_in_Patients_with_Relapsed_Refractory_CLL_or_SLL_in_the_DUO_Crossover_Extension_Study/22480008/1/files/39931521.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"doi:10.1158/1078-0432.22480008.v1","doi":"https://doi.org/10.1158/1078-0432.22480008.v1","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.22480008.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"pmh:oai:figshare.com:article/22480008","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/journal_contribution/Supplementary_Tables_1-5_from_Efficacy_and_Safety_of_Duvelisib_Following_Disease_Progression_on_Ofatumumab_in_Patients_with_Relapsed_Refractory_CLL_or_SLL_in_the_DUO_Crossover_Extension_Study/22480008","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.22480008","doi":"https://doi.org/10.1158/1078-0432.22480008","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.22480008","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Tables_1-5_from_Efficacy_and_Safety_of_Duvelisib_Following_Disease_Progression_on_Ofatumumab_in_Patients_with_Relapsed_Refractory_CLL_or_SLL_in_the_DUO_Crossover_Extension_Study/22480008/1/files/39931521.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9907000064849854}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4361815427.pdf","grobid_xml":"https://content.openalex.org/works/W4361815427.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4361815526","https://openalex.org/W3001171775","https://openalex.org/W2891876928","https://openalex.org/W2905375175","https://openalex.org/W2951349998","https://openalex.org/W2961546232","https://openalex.org/W2784823232","https://openalex.org/W2950306720","https://openalex.org/W2951800991","https://openalex.org/W2988180727"],"abstract_inverted_index":{"\u2022Table":[0,16,47,92],"S1":[1],"shows":[2,18,49,78,94],"a":[3,95],"summary":[4,96],"of":[5,27,35,51,69,80,97],"prior":[6],"anticancer":[7],"therapies":[8],"received":[9],"by":[10,29],"all":[11,52,81],"patients":[12,36,70,87],"in":[13,31,40,62,71,86,88],"the":[14,32,41,72,89],"study":[15,33,44,73,90],"S2":[17],"best":[19],"overall":[20,22],"response,":[21],"response":[23,28],"rate,":[24],"and":[25,55,58],"duration":[26],"investigator":[30],"population":[34,74,91],"while":[37],"receiving":[38],"ofatumumab":[39],"parent":[42],"DUO":[43],"before":[45],"crossover":[46],"S3":[48],"rates":[50,79],"serious":[53,60],"TEAEs":[54,61,82],"individual":[56],"hematologic":[57],"non-hematologic":[59],"{greater":[63],"than":[64],"or":[65],"equal":[66],"to}":[67],"2%":[68],"\u2022":[75],"Table":[76],"S4":[77],"leading":[83],"to":[84],"death":[85],"S5":[93],"patient":[98],"disposition":[99],"information":[100]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2023-04-05T00:00:00"}